Needham & Company Downgrades Vertex (VRTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Maxim Group Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:30 AM ESTMaxim Group downgraded Vertex (NASDAQ: VRTX) from Buy to Hold with a price target of $121.00 (from $148.00).
Analyst Jason Kolbert commented:
Vertex reported YE2014 non-GAAP revenue and operating expenses of $536M and $920M, respectively, and a non-GAAP loss of $511M and EPS of ($2.17). Revenue was driven largely by Kalydeco sales of $464M. Vertex enters 2015 with... MoreVertex Pharma (VRTX) Posts Smaller Q4 Loss
January 28, 2015 4:11 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $145 million versus the consensus estimate of $137.5 million.
"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label... More
